Drugmakers Pay Millions To Government Under First PPRS Rebate
BMI View : T he UK has traditionally had high state healthcare expenditure, with patients enjoying free access to doctors and specialists , and easy access to medicines. However, the government currently accounts for more than three-quarters of healthcare spending, and the expanding, ageing population will continue boost the demand for healthcare , pushing the government to focus on cost containment.
Highlighting revenue pressures for innovative drugmakers operating in the UK, on 30 June 2014, the Association of the British Pharmaceutical Industry (ABPI) and the UK's Department of Health announced the payment of a rebate of GBP74mn (USD126mn) by industry to underwrite the growth in the branded medicines bill under the 2014 Pharmaceutical Price Regulation Scheme (PPRS). The payment accounts for the first three months of 2014.
Controlled Expenditure On Branded Medicines